{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-138253","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.223440+00:00","generated_at":"2026-06-02T01:07:16.651354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Taysha Q1 net loss $24.1M; TSHA-102 advances to high-dose cohort, gets RMAT designation","bullets":["Q1 net loss of $24.1M ($0.10/share) vs $17.6M loss a year ago; R&D expenses $20.7M.","FDA granted RMAT designation for TSHA-102 for Rett syndrome based on early safety/efficacy data.","Completed low-dose cohort in REVEAL adult trial; enrolled first patient in high-dose (1x10^15 vg) for Q2 dosing.","Second pediatric patient dosed in low-dose cohort; initial data from both trials expected mid-2024.","Cash $124M; expects to fund operations into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-138253","json":"https://secwatch.observer/filing/0001193125-24-138253.json","markdown":"https://secwatch.observer/filing/0001193125-24-138253.md","text":"https://secwatch.observer/filing/0001193125-24-138253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524138253/0001193125-24-138253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524138253/d833929d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:07:16.651354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"893dd7fb7d0fda179eb0395f445d439ebefcae0f","claim":"Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Taysha Gene Therapies, Inc. reported financial results and business highlights for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524138253/0001193125-24-138253-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}